You’re getting confused.
I think the 57% tumour volume reduction was in a study conducted in Adelaide on people with metastatic disease. Although there wasn’t curative intent the tumour volume was reduced by half. Given that most people with pancreatic cancer die from local spread (liver, bile ducts, peritoneum) reducing volume means slower spread and less symptoms hopefully. And it’s a much bigger group/market because the disease is usually diagnosed after it has spread.
OncoSil advancements in Pancreatic Cancer Treatment, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
